Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Variability of the Response to Immunotherapy Among Subgroups of Patients With Multiple Sclerosis Publisher Pubmed



Diouf I1 ; Malpas CB1, 2 ; Sharmin S1 ; Roos I1, 2 ; Horakova D3 ; Havrdova EK3 ; Patti F4 ; Shaygannejad V5 ; Ozakbas S6 ; Izquierdo G7 ; Eichau S7 ; Onofrj M8 ; Lugaresi A9, 10 ; Alroughani R11 Show All Authors
Authors
  1. Diouf I1
  2. Malpas CB1, 2
  3. Sharmin S1
  4. Roos I1, 2
  5. Horakova D3
  6. Havrdova EK3
  7. Patti F4
  8. Shaygannejad V5
  9. Ozakbas S6
  10. Izquierdo G7
  11. Eichau S7
  12. Onofrj M8
  13. Lugaresi A9, 10
  14. Alroughani R11
  15. Prat A12
  16. Girard M12
  17. Duquette P12
  18. Terzi M13
  19. Boz C14
  20. Grandmaison F15
  21. Hamdy S16
  22. Sola P17
  23. Ferraro D17
  24. Grammond P18
  25. Turkoglu R19
  26. Buzzard K20
  27. Skibina O20
  28. Yamout B21
  29. Altintas A22, 23
  30. Gerlach O24
  31. Van Pesch V25
  32. Blanco Y26
  33. Maimone D27
  34. Lechnerscott J28
  35. Bergamaschi R29
  36. Karabudak R30
  37. Iuliano G31
  38. Mcguigan C32
  39. Cartechini E33
  40. Barnett M34
  41. Hughes S35
  42. Sa MJ36
  43. Solaro C37, 38
  44. Kappos L39
  45. Ramotello C40
  46. Cristiano E41
  47. Hodgkinson S42
  48. Spitaleri D43
  49. Soysal A44
  50. Petersen T45
  51. Slee M46
  52. Butler E47
  53. Granella F48
  54. De Gans K49
  55. Mccombe P50
  56. Ampapa R51
  57. Vanwijmeersch B52
  58. Van Der Walt A20, 53
  59. Butzkueven H54
  60. Prevost J55
  61. Sinnige LGF56
  62. Sanchezmenoyo JL57
  63. Vucic S58
  64. Laureys G59
  65. Vanhijfte L59
  66. Khurana D60
  67. Macdonell R54
  68. Gouider R61
  69. Castillotrivino T62
  70. Gray O63
  71. Agueramorales E64
  72. Alasmi A65
  73. Shaw C66
  74. Deri N67
  75. Alharbi T68
  76. Fragoso Y69
  77. Csepany T70
  78. Perezsempere A71
  79. Trevinofrenk I72
  80. Schepel J73
  81. Moore F74
  82. Kalincik T1, 2

Source: European Journal of Neurology Published:2023


Abstract

Background and purpose: This study assessed the effect of patient characteristics on the response to disease-modifying therapy (DMT) in multiple sclerosis (MS). Methods: We extracted data from 61,810 patients from 135 centers across 35 countries from the MSBase registry. The selection criteria were: clinically isolated syndrome or definite MS, follow-up ≥ 1 year, and Expanded Disability Status Scale (EDSS) score ≥ 3, with ≥1 score recorded per year. Marginal structural models with interaction terms were used to compare the hazards of 12-month confirmed worsening and improvement of disability, and the incidence of relapses between treated and untreated patients stratified by their characteristics. Results: Among 24,344 patients with relapsing MS, those on DMTs experienced 48% reduction in relapse incidence (hazard ratio [HR] = 0.52, 95% confidence interval [CI] = 0.45–0.60), 46% lower risk of disability worsening (HR = 0.54, 95% CI = 0.41–0.71), and 32% greater chance of disability improvement (HR = 1.32, 95% CI = 1.09–1.59). The effect of DMTs on EDSS worsening and improvement and the risk of relapses was attenuated with more severe disability. The magnitude of the effect of DMT on suppressing relapses declined with higher prior relapse rate and prior cerebral magnetic resonance imaging activity. We did not find any evidence for the effect of age on the effectiveness of DMT. After inclusion of 1985 participants with progressive MS, the effect of DMT on disability mostly depended on MS phenotype, whereas its effect on relapses was driven mainly by prior relapse activity. Conclusions: DMT is generally most effective among patients with lower disability and in relapsing MS phenotypes. There is no evidence of attenuation of the effect of DMT with age. © 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Other Related Docs
8. Comparison of Fingolimod, Dimethyl Fumarate and Teriflunomide for Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2019)
14. Disability Accrual in Primary and Secondary Progressive Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2023)